Oncology

What challenges should teams conducting blood cancer clinical trials anticipate? Learn more about common obstacles and how to overcome them.

RECIST criteria is not always reported accurately, and variability in tumor response assessment may be disastrous for measuring true treatment effect. Here’s how your CRO can support more consistent RECIST reads.

What do you need to consider when managing/monitoring an immuno-oncology clinical trial? Download PharPoint’s fact book to learn more.

PharPoint Research is thrilled to be a CRO Sponsor for the Spring 2021 Oncology Investor Conference. This event is the preeminent investment event in oncology – for investors seeking to invest in private and public cancer companies, and for cancer related companies seeking investment.